Active surveillance redefines paradigm for prostate cancer management

Active surveillance — in which prostate cancer is regularly monitored for signs of progression — spares men whose tumors may never progress from potential treatment-associated adverse effects, such as sexual dysfunction or incontinence. Proponents contend active surveillance is a viable option because mortality rates among men whose tumors are limited to the prostate are low, and many of these men never experience symptoms from their disease. However, some urologic oncologists question active surveillance as a standard management strategy and contend its use should be limited. Read the article.

International institutions agree on standard for using MR to diagnose prostate cancer

A new standard for evaluating MR images to diagnose prostate cancer has been agreed upon by international radiological institutions and is now published in the journal European Urology. The new procedure reduces the over-diagnosis of insignificant cancers by up to 89 percent and assists in the diagnosis of up to 13 percent more life-threatening tumors than current procedures. Read the article.

Some Prostate Cancer Patients May Not Benefit From Hormone Therapy

Men with prostate cancer who also have had a heart attack may fare better with radiation therapy alone rather than with the standard treatment of radiation plus hormone therapy, a new analysis suggests. Over an average of 17 years of follow-up, men with high-risk prostate cancer who also had a heart condition lived longer after radiation treatment alone than similar men who had radiation and hormone therapy. Men who didn’t have heart problems lived longer if they had both treatments, the researchers added. Read the article.

Revolutionary prostate biopsy approach more accurate at diagnosing prostate cancer

A revolutionary prostate biopsy approach uses fewer needles and is more accurate for diagnosing prostate cancer. It is done during a real time MRI (magnetic resonance imaging) scan that clearly shows suspicious sites. When done by an expert radiologist using a highly powerful magnet, only a minimum number of needles are used to sample suspicious abnormalities. Read the article.

Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy

The study provides compelling evidence that few benign cancer suspicious regions increase in suspicion score and/or the greatest linear measurement within 1 year independent of the baseline suspicion score. Therefore, routinely repeating multiparametric magnetic resonance imaging at 1 year in men with pathologically benign cancer suspicious regions should be discouraged since it is unlikely to influence management decisions. Read the article.

High-dose-rate brachytherapy (HDRBT) monotherapy — 10 year results

High-dose-rate (HDR) brachytherapy was originally used with external beam radiation therapy (EBRT) to increase the dose to the prostate without injuring the bladder or rectum. Numerous studies have reported HDR brachytherapy is safe and effective. It has been adapted for use without EBRT for cases not requiring lymph node treatment. Read the article.

Scroll to Top